FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022871861> ?p ?o ?g. }

• W2022871861 endingPage "529" @default.
• W2022871861 startingPage "523" @default.
• W2022871861 abstract "This study examines the expression of the cell–cell adhesion molecules E-cadherin and its associated proteins, the catenins and the matrix–cell adhesion molecules β1- and α2-integrins, in primary invasive breast carcinoma. Expression was assessed immunohistochemically on frozen sections by semi-quantitative scoring of the intensity and proportion of immunoreactivity in 55 cases. Associations with each other and with other histological and prognostic features and survival were sought. There was a significant association between loss of E-cadherin expression and loss of α- and β/γ-catenin immunostaining. In 20 per cent of cases, membranous immunoreactivity with E-cadherin antibody was absent. Absent cytoplasmic expression of α- and β/γ-catenins was seen in 24 and 22 per cent of breast cancers, respectively. The intensity of reactivity with E-cadherin showed a significant association with histological grade (p = 0·002) and tumour type (p < 0·001). Lobular carcinomas frequently showed loss of expression of E-cadherin, as reported elsewhere; loss of catenin expression was also found in these tumours. α-Catenin intensity also showed a relationship with grade (p = 0·008) and with oestrogen receptor (ER) status (p = 0·006). β/γ-Catenin expression was not associated with other known prognostic factors. Forty-nine per cent and 42 per cent of cases showed no membrane immunostaining with β1- and α2-integrin, respectively, and co-ordinated loss of β1- and α2-integrin expression was found. Both β1- and α2-integrin expression were associated with histological grade (p = 0·003 and p = 0·031, respectively) and β1 immunoreactivity with tumour type (p = 0·010). None of the variables examined showed a statistically significant association with tumour size or lymph node stage, or with overall survival, although a trend was seen (p = 0·087) towards poorer survival of patients with tumours with absent or weak expression of β1-integrin. The expression of these markers is of biological interest, but appears to be of little additional use in predicting clinical behaviour. Copyright © 1999 John Wiley & Sons, Ltd." @default.
• W2022871861 created "2016-06-24" @default.
• W2022871861 creator A5000183024 @default.
• W2022871861 creator A5005645499 @default.
• W2022871861 creator A5008360423 @default.
• W2022871861 creator A5019290079 @default.
• W2022871861 creator A5033047897 @default.
• W2022871861 creator A5055005629 @default.
• W2022871861 creator A5073889721 @default.
• W2022871861 creator A5075105813 @default.
• W2022871861 creator A5079123323 @default.
• W2022871861 date "1999-04-01" @default.
• W2022871861 modified "2023-10-16" @default.
• W2022871861 title "An immunohistochemical examination of the expression of E-cadherin, ?- and ?/?-catenins, and ?2- and ?1-integrins in invasive breast cancer" @default.
• W2022871861 cites W1534652806 @default.
• W2022871861 cites W1973438540 @default.
• W2022871861 cites W1974712385 @default.
• W2022871861 cites W1977860453 @default.
• W2022871861 cites W1986657548 @default.
• W2022871861 cites W2001575298 @default.
• W2022871861 cites W2010871781 @default.
• W2022871861 cites W2012246828 @default.
• W2022871861 cites W2015183711 @default.
• W2022871861 cites W2033272151 @default.
• W2022871861 cites W2036457169 @default.
• W2022871861 cites W2038666759 @default.
• W2022871861 cites W2041123249 @default.
• W2022871861 cites W2067365317 @default.
• W2022871861 cites W2082414225 @default.
• W2022871861 cites W2083990005 @default.
• W2022871861 cites W2105500381 @default.
• W2022871861 cites W2111433647 @default.
• W2022871861 cites W2115146277 @default.
• W2022871861 cites W2116615268 @default.
• W2022871861 cites W2119593627 @default.
• W2022871861 doi "https://doi.org/10.1002/(sici)1096-9896(199904)187:5<523::aid-path296>3.0.co;2-3" @default.
• W2022871861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10398116" @default.
• W2022871861 hasPublicationYear "1999" @default.
• W2022871861 type Work @default.
• W2022871861 sameAs 2022871861 @default.
• W2022871861 citedByCount "94" @default.
• W2022871861 countsByYear W20228718612012 @default.
• W2022871861 countsByYear W20228718612013 @default.
• W2022871861 countsByYear W20228718612014 @default.
• W2022871861 countsByYear W20228718612015 @default.
• W2022871861 countsByYear W20228718612016 @default.
• W2022871861 countsByYear W20228718612017 @default.
• W2022871861 countsByYear W20228718612018 @default.
• W2022871861 countsByYear W20228718612019 @default.
• W2022871861 countsByYear W20228718612020 @default.
• W2022871861 countsByYear W20228718612022 @default.
• W2022871861 crossrefType "journal-article" @default.
• W2022871861 hasAuthorship W2022871861A5000183024 @default.
• W2022871861 hasAuthorship W2022871861A5005645499 @default.
• W2022871861 hasAuthorship W2022871861A5008360423 @default.
• W2022871861 hasAuthorship W2022871861A5019290079 @default.
• W2022871861 hasAuthorship W2022871861A5033047897 @default.
• W2022871861 hasAuthorship W2022871861A5055005629 @default.
• W2022871861 hasAuthorship W2022871861A5073889721 @default.
• W2022871861 hasAuthorship W2022871861A5075105813 @default.
• W2022871861 hasAuthorship W2022871861A5079123323 @default.
• W2022871861 hasConcept C121608353 @default.
• W2022871861 hasConcept C126322002 @default.
• W2022871861 hasConcept C137620995 @default.
• W2022871861 hasConcept C142724271 @default.
• W2022871861 hasConcept C1491633281 @default.
• W2022871861 hasConcept C149402561 @default.
• W2022871861 hasConcept C16224149 @default.
• W2022871861 hasConcept C170493617 @default.
• W2022871861 hasConcept C195687474 @default.
• W2022871861 hasConcept C203014093 @default.
• W2022871861 hasConcept C204232928 @default.
• W2022871861 hasConcept C30145163 @default.
• W2022871861 hasConcept C4224716 @default.
• W2022871861 hasConcept C530470458 @default.
• W2022871861 hasConcept C54355233 @default.
• W2022871861 hasConcept C62478195 @default.
• W2022871861 hasConcept C71924100 @default.
• W2022871861 hasConcept C86803240 @default.
• W2022871861 hasConcept C95444343 @default.
• W2022871861 hasConceptScore W2022871861C121608353 @default.
• W2022871861 hasConceptScore W2022871861C126322002 @default.
• W2022871861 hasConceptScore W2022871861C137620995 @default.
• W2022871861 hasConceptScore W2022871861C142724271 @default.
• W2022871861 hasConceptScore W2022871861C1491633281 @default.
• W2022871861 hasConceptScore W2022871861C149402561 @default.
• W2022871861 hasConceptScore W2022871861C16224149 @default.
• W2022871861 hasConceptScore W2022871861C170493617 @default.
• W2022871861 hasConceptScore W2022871861C195687474 @default.
• W2022871861 hasConceptScore W2022871861C203014093 @default.
• W2022871861 hasConceptScore W2022871861C204232928 @default.
• W2022871861 hasConceptScore W2022871861C30145163 @default.
• W2022871861 hasConceptScore W2022871861C4224716 @default.
• W2022871861 hasConceptScore W2022871861C530470458 @default.
• W2022871861 hasConceptScore W2022871861C54355233 @default.
• W2022871861 hasConceptScore W2022871861C62478195 @default.
• W2022871861 hasConceptScore W2022871861C71924100 @default.
• W2022871861 hasConceptScore W2022871861C86803240 @default.

• next